Fast Facts: Biosimilars /
Biologic medicines have revolutionized the treatment of many serious disorders. Biosimilars offer similar safety and efficacy at a fraction of the cost, though while they have led to significant savings, uptake varies globally due to concerns and regulatory inconsistencies, especially in middle-inco...
Enregistré dans:
| Autres auteurs: | |
|---|---|
| Format: | Livre numérique |
| Langue: | Anglais |
| Publié: |
Basel :
S. Karger
2024.
Basel : |
| Accès en ligne: | Accès Université d'Orléans et IFPM |
| Note: |
Karger Fast Facts |
| Autres localisations: | Voir dans le Sudoc |
| Edition sous un autre format: | • Fast Facts: Biosimilars, 9783318060805 |
| LEADER | 02291nam a22002057a 4500 | ||
|---|---|---|---|
| 001 | 1461540 | ||
| 008 | 250606s2024 xx ||| |||| 00| 0 eng d | ||
| 009 | PPN285255258 | ||
| 020 | |a 9783318073836 | ||
| 041 | 0 | |a eng | |
| 245 | 1 | 0 | |a Fast Facts: Biosimilars / |c edited by Guy Regnard. |
| 260 | |a Basel : |b S. Karger. | ||
| 260 | |a Basel : |b S. Karger, |c 2024. | ||
| 500 | |a Karger Fast Facts | ||
| 506 | |a Accès libre pour tout établissements ou utilisateur ayant un compte sur la plateforme de l'éditeur | ||
| 520 | |a Biologic medicines have revolutionized the treatment of many serious disorders. Biosimilars offer similar safety and efficacy at a fraction of the cost, though while they have led to significant savings, uptake varies globally due to concerns and regulatory inconsistencies, especially in middle-income countries where the need for affordable drugs is greatest. 'Fast Facts: Biosimilars: A Global Perspective' has taken a specifically global perspective, with expert contributors invited to represent a range of medical specialties, including endocrinology, hematology, oncology and immunology, and regions of the world. It addresses the following concerns, drawing on the most up-to-date information in this fast-moving area of medicine:<list list-type="bullet"><list-item><p>Is the quality of the biosimilar medicine equivalent to that of the original drug?</p></list-item><list-item><p>Is the biosimilar medicine safe?</p></list-item><list-item><p>Which indications can the biosimilar medicine be used for?</p></list-item><list-item><p>What are the realistic economic benefits?</p></list-item><list-item><p>How do I switch a patient from a biologic to an equivalent biosimilar medicine?</p></list-item> <list-item><p>How do I select biologics in a region with regulatory uncertainty over biosimilars?</p></list-item> <list-item><p>How do I explain biosimilars to patients?</p></list-item></list> | ||
| 700 | 1 | |a Regnard, Guy. |4 pbd | |
| 776 | 0 | |t Fast Facts: Biosimilars |z 9783318060805 | |
| 856 | 4 | |5 452349901:889241015 |u https://ezproxy.univ-orleans.fr/login?url=https://karger.com/books/book/6006 |z Accès Université d'Orléans et IFPM | |
| 997 | |0 1461540 |1 Livre numérique |a Ressource numérique |b INSA |b ENSA |c 0/Bibliothèque numérique/ |c 1/Bibliothèque numérique/Autre ressource numérique/ | ||